NCT07228975 is a NA clinical trial of MetrioFen Gocce in Endometriosis, sponsored by Endok s.r.l..

Who is sponsoring NCT07228975?

NCT07228975 is sponsored by Endok s.r.l..

What drugs are being tested in NCT07228975?

Interventions in NCT07228975: MetrioFen Gocce.

What condition does NCT07228975 study?

NCT07228975 studies Endometriosis.

Is NCT07228975 still recruiting?

NCT07228975 is currently completed. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT07228975

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study on a Dietary Supplement With EndoGen™ as Adjunct Therapy in Women With Endometriosis

Completed NA Last updated 20 November 2025

What this trial tests

NA trial testing MetrioFen Gocce in Endometriosis in 36 participants. Completed in 31 July 2025.

Timeline

9 September 2024

Primary endpoint
31 July 2025

31 July 2025

Quick facts

Lead sponsor	Endok s.r.l.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	9 September 2024
Primary completion	31 July 2025
Estimated completion	31 July 2025
Sites	7 locations across Italy

Drugs / interventions tested

MetrioFen Gocce

Conditions studied

Endometriosis — all drugs for Endometriosis →

Sponsor

Endok s.r.l.

Who can join

Adults 18 to 45, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Current treatments for endometriosis, such as NSAIDs and hormone therapies, are meant for long-term use but often cause side effects, including stomach, liver, heart, and kidney issues; allergies; and hormonal problems like weight gain, acne, and bone loss. Therefore, one option being studied is a food supplement based on parsley extract (Petroselinum crispum), rosemary extract (Rosmarinus Officinalis L.), and selenium, combined with mountain celery and Vitamins B6, D, and E. The study's goal is to show improvement in pain and reduced use of NSAIDs in fertile women with endometriosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

NCT06559852 — The Impact of Yoga on Endometriosis-Related Pain · NA · recruiting
NCT07393295 — Efficacy and Tolerability of TENS in Endometriosis-related Pain · NA · recruiting
NCT07134023 — Educational Program for the Multidisciplinary Support of Patients With Endometriosis · NA · recruiting
NCT07240883 — ENDO1000 - A UK-wide Endometriosis Research Project · recruiting
NCT06974773 — Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07228975 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endok s.r.l.
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07228975.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing